Researchers are developing a nasal spray that could one day treat people with post-traumatic stress disorder (PTSD).
The project is being led by Southwest Research Institute (SwRI) and Trinity University in San Antonio, Texas.
The team will screen formulations and evaluate delivery methods for oxytocin, a hormone involved in bonding and stress relief.
The work builds on earlier joint research into treating alcoholism and relapse with oxytocin.
SwRI supported that project by formulating oxytocin using liposomes, nanosized protective spheres made of organic compounds that ensure targeted delivery in the body.
Dr Mike Rubal, staff scientist at SwRI, said: “Internasal delivery of liposomes bypasses the blood-brain barrier and allows the drug direct access to the central nervous system.
“In addition, the IN-delivery process has commercial precedence with other Food and Drug Administration-approved liposome-drug combinations, making future advancements more feasible.”
Researchers at Trinity will test the devices and drug formulations on animal models preconditioned for PTSD behaviour.
Findings will inform optimisation of formulations and delivery systems to improve efficacy and palatability.
PTSD can affect people of all ages who experience trauma, including combat veterans and survivors of abuse.
Symptoms vary but include prolonged stress, sleep problems, irritability and aggressive behaviours.
Dr Kah-Chung Leong, associate professor in the department of psychology at Trinity University, said: “This project will enhance the collaborative environment between SwRI and Trinity and opens the door for further advancements in biomedical research here in San Antonio.”
